How Can We Apply Guidelines in the Rapidly Changing MS Treatment Landscape?

How Can We Apply Guidelines in the Rapidly Changing MS Treatment Landscape?

Publication date: Nov 26, 2019

Management of multiple sclerosis (MS) occurs in a rapidly changing environment in which decisions must be made using the latest available data and insights. This webinar serves as a review and update to the CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis, published in early 2019. These guidelines were developed based on a consensus conference independently convened in 2018 by the Consortium of Multiple Sclerosis Centers (CMSC) among a group of MS experts. As the year 2019 comes to a close, program chairs Corey Ford and Sarah Morrow will review key points of the guideline states, focusing in on current “hot topics” in MS management and that latest updates that arose throughout the year.

Credit Types

AAPA: 1.00

ACPE: 1.00

CME: 1.00

CNE: 1.00

CNE – Pharmacology: 1.00

Letter of Completion: 1.00

Release Date: December 2, 2019

Valid for Credit Through: December 31, 2020

Concepts Keywords
Acid Imaging
Adverse Event Oil treatments
Africa Therapies Multiple Sclerosis
AKEL Therapy multiple sclerosis
Albuquerque Areas inflammation
Antibodies DiSanto multiple sclerosis
Apologize Fatigue
Apple Burns
Asian Activity ongoing inflammation
Atoll Active initial disease
Avonex MS
Basal Ganglia Risk birth defects
Benign Cognitive impairment
Berry Routine inflammation
Brain Infection
Breakthrough Therapy System emails depression
Burrito Course relapse disease
Canada Significant fatigue
Canadian Syndrome
Cardiac Rhythm Medicine
Catelyn Medical specialties
Clinical Trial Health
CMS Autoimmune diseases
Cognitive Depression
Continuing Education Immunosuppressants
Depression Psychiatric diagnosis
Diabetes Multiple sclerosis
Disability Therapy
Emery Natalizumab
Enzyme Major depressive disorder
FDA Interferon beta-1a
FEMA Antibodies
FINA MRI
Ford Flash
Frequency
Gal
Gallon
Gambling
Gender
Genzyme
Glitter
God
Gollum
Hedorah
Hema
Hepatitis
HIV
Hybrid
IAM
Immune System
Immunosuppressants
Infection
Inflammation
ISI
Kidney
Legions
Lesion
Lime
Localism
London
Lymphocytes
Mab
Madeira
Mantra
Memory
Mexico
Milligram
Mm
Moat
Monocle
Monoclonal Antibodies
Mora
Morbidity
MRI
Multiple Sclerosis
Neurological
Neurology
North America
Oil
Okra
Ontario
Opera
Pediatric
Placebo
PML
Pregnancy
Primary Endpoint
Prognosis
Progressive
Qlogic
Realism
Relapse
Remission
Sabine
Sanofi
Serono
Side Control
Silent
Spinal Cord
Summer Time
Tate
Tea
Titrate
Tuberculosis
Tysabri
Virus
Waas
Webinar

Semantics

Type Source Name
disease MESH multiple sclerosis
pathway REACTOME Release

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *